Scinopharm Taiwan, Ltd.

Vanderbilt University

Scinopharm (Kunshan) Biochemical Technology Co., Ltd.

Biomide Investment Limited Partnership

Scinopharm Biochemical Technology Co., Ltd.

Yung-Fa Chen

Julian Paul Henschke

Yuanlian Liu

Xiaoheng Zhang

Ting Sun

Dechao Meng

Lawrence J Marnett

Kenneth V Honn

Carl R Johnson

Katsu-ichi Shimoji

Julian P Henschke

Lizhen Xia

George Schloemer

Shu-Ping Chen

Lijun Mei

Meng-Fen Ho

Guodong Chu

Kau-Ming Chen

Chien Hsin Lin

Wlodzimierz Daniewski

Chien-Hsing Lin

Yong Mu

ChunFang Xu

YiJing Chen

Julian Henschke

Intermediates of the following formulae for the preparation of lubiprostone: 

Intermediates for the preparation of lubiprostone

The present invention provides amorphous forms and the crystalline complexes of SGLT2 inhibitors as a novel material, in particular in pharmaceutically acceptable form. The crystalline forms of SGLT2 inhibitor canagliflozin are designated as Forms CS1, CS2, CS3, CS4 and CS5.

Crystalline and non-crystalline forms of SGLT2 inhibitors

Processes for preparing and purifying lubiprostone are disclosed. Intermediates and preparation thereof are also disclosed.

Process for the preparation of lubiprostone

The present invention provides for synthetic processes for the making of substituted 3-((pyrrol-2-yl)methylene)-2-pyrrolones, including sunitinib. The present invention also provides for a process of crystallizing substantially pure sunitinib L-malate.

Processes for the preparation of 3-(pyrrol-2-yl)methylene)-2-pyrrolones using 2-silyloxy-pyrroles

A process for preparing a prostaglandin analogue comprising a step of converting a compound of formula (8'): to the prostaglandin analogue, wherein Rrepresents hydrogen or a hydroxyl protecting group.

Process for the preparation of prostaglandin analogues

A compound of formula (X): which can be used as an intermediate to make lapatinib or its pharmaceutically acceptable salt.

Process and intermediates for preparing lapatinib

A process for making clofarabine comprising: fluorinating a compound of formula VII wherein each Ris independently a hydroxy protecting group, ORis a leaving group, with a fluorinating agent in the presence of guanidine carbonate to give a compound of formula VIII: 

Preparation of 2-chloro-9-(2'-deoxy-2&#x2032;-fluoro-&#x3b2;-D-arabinofuranosyl)-adenine

The present invention provides a process for making lapatinib and its pharmaceutically acceptable salt by use of new intermediates. A new process for obtaining a pharmaceutical form of lapatinib ditosylate monohydrate is also provided.

The present application provides intermediates for preparing prostaglandin analogues and processes for preparing prostaglandin analogues and intermediates thereof. The intermediates include: A compound of formula (6): Rrepresents H, C-C-alkyl, or benzyl, in particular isopropyl.

Process for the preparation of prostaglandin analogues and intermediates thereof

The key intermediate in any synthesis of Irinotecan is 7-ethyl-10-hydroxy-20(S)-camptothecin. A process for the efficient synthesis of this intermediate is demonstrated proceeding through readily available 20(S)-camptothecin. Various other tecan compounds may be made by use of corresponding 7-alkyl-10-hydroxy-20(S)-camptothecin intermediates.

Process for the preparation of 7-alkyl-10-hydroxy-20(S)-camptothecin

The present invention provides a novel semi-synthetic method of producing a variety of novel taxane derivatives. The method involves the reaction of a phenylisoserine derivative with a suitably blocked Baccatin III derivative to produce a taxane substrate that may be further modified to form Pactitaxel and other potentially useful taxane derivatives.

Process for making taxane derivatives

This invention is related to a cyclic hydroxamic acid of the formula: ##STR1## wherein R.sup.1 is C.sub.1-24 alkyl and R.sup.2 is benzyl.

Cyclic hydroxamic acids

Novel cyclic hydroxamic acids of the general formula: ##STR1## wherein ring A is 5- or 6-membered; R.sup.1, R.sup.2 and R.sup.3 each, ipendently, is hydrogen, C1-24 alkyl, C2-24 alkenyl or a group of the formula: ##STR2## wherein R.sup.4, R.sup.5, R.sup.7 and R.sup.8 each, independently is hydrogen,

Growing community of inventors

Tainan, Taiwan

Yung-Fa Chen